Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial

Emma Del Carmen Macías-Cortés, Lidia Llanes-González, Leopoldo Aguilar-Faisal, Juan Asbun-Bojalil, Emma Del Carmen Macías-Cortés, Lidia Llanes-González, Leopoldo Aguilar-Faisal, Juan Asbun-Bojalil

Abstract

Background: Perimenopausal period refers to the interval when women's menstrual cycles become irregular and is characterized by an increased risk of depression. Use of homeopathy to treat depression is widespread but there is a lack of clinical trials about its efficacy in depression in peri- and postmenopausal women. The aim of this study was to assess efficacy and safety of individualized homeopathic treatment versus placebo and fluoxetine versus placebo in peri- and postmenopausal women with moderate to severe depression.

Methods/design: A randomized, placebo-controlled, double-blind, double-dummy, superiority, three-arm trial with a 6 week follow-up study was conducted. The study was performed in a public research hospital in Mexico City in the outpatient service of homeopathy. One hundred thirty-three peri- and postmenopausal women diagnosed with major depression according to DSM-IV (moderate to severe intensity) were included. The outcomes were: change in the mean total score among groups on the 17-item Hamilton Rating Scale for Depression, Beck Depression Inventory and Greene Scale, after 6 weeks of treatment, response and remission rates, and safety. Efficacy data were analyzed in the intention-to-treat population (ANOVA with Bonferroni post-hoc test).

Results: After a 6-week treatment, homeopathic group was more effective than placebo by 5 points in Hamilton Scale. Response rate was 54.5% and remission rate, 15.9%. There was a significant difference among groups in response rate definition only, but not in remission rate. Fluoxetine-placebo difference was 3.2 points. No differences were observed among groups in the Beck Depression Inventory. Homeopathic group was superior to placebo in Greene Climacteric Scale (8.6 points). Fluoxetine was not different from placebo in Greene Climacteric Scale.

Conclusion: Homeopathy and fluoxetine are effective and safe antidepressants for climacteric women. Homeopathy and fluoxetine were significantly different from placebo in response definition only. Homeopathy, but not fluoxetine, improves menopausal symptoms scored by Greene Climacteric Scale.

Trial registration: ClinicalTrials.gov NCT01635218.

Protocol publication: https://ichgcp.net/clinical-trials-registry/NCT01635218 [corrected].

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. CONSORT flow diagram of study…
Fig 1. CONSORT flow diagram of study participants through the trial.
Fig 2. Mean change in 17-item Hamilton…
Fig 2. Mean change in 17-item Hamilton Rating Scale for Depression score after six weeks of treatment according to the study group.
HRSD scores range from 0 (no depression) up to 52 (maximum depression severity). IHT and flouxetine groups improved significantly faster than placebo group. І bars denote 95% CI.
Fig 3. Mean change in Beck Depression…
Fig 3. Mean change in Beck Depression Inventory score after six weeks of treatment according to the study group.
BDI scores range from 0 (no depression) up to 63 (maximum depression severity). IHT and flouxetine groups did not improve significantly faster than placebo group. І bars denote 95% CI.
Fig 4. Mean change in Greene Climacteric…
Fig 4. Mean change in Greene Climacteric Scale score after six weeks of treatment according to the study group.
GS scores range from 0 (without climacteric symptoms) up to 63 (most severe climacteric symptoms). IHT improved significantly faster than placebo group. І bars denote 95% CI.

References

    1. Kessler RC. Epidemiology of women and depression. J Affect Disord. 2003; 74 (1): 5–13.
    1. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am J Psychiatry. 1994; 151 (7): 979–986.
    1. Wise PM, Krajnak KM, Kashon ML. Menopause: the aging of multiple pacemakers. Science. 1996; 273: 67–70.
    1. Shifren JL, Schiff I. The aging ovary. J Womens Health Gend Based Med 9 (suppl 1). 2000; S3–S7.
    1. World Health Organization. Research on the Menopause in the 1990s Report of a WHO Scientific Group. WHO Technical Report Series; 1996.
    1. Bungay GT, Vessey MP, McPherson CK. Study of symptoms in middle life with special reference to the menopause. BMJ. 1980; 281 (6234): 181–183.
    1. Holte A, Mikkelsen A. The menopausal syndrome: a factor analytic replication. Maturitas. 1991; 13 (3): 193–203.
    1. Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS. Endocrine features of menstrual cycle in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) Staging System. J Clin Endocrinol Metab. 2007; 92: 3060–3067.
    1. Clayton AH, Ninan PT. Depression or menopause? Presentation and management of major depressive disorder in perimenopausal and postmenopausal women. J Clin Psychiatry. 2010; 12(1): PCC.08r00747. 10.4088/PCC.08r00747blu
    1. Soares CN, Cohen LS. Perimenopause and mood disturbance: an update. CNS Spectr. 2001; (6) 2: 167–174.
    1. Bromberger JT, Matthews KA, Schott LL, Brockwell S, Avis NE, Kravitz HM, et al. Depressive symptoms during the menopausal transition: The Study of Women's Health Across the Nation (SWAN). J Affect Disord. 2007; 103 (1–3): 267–272.
    1. Hay AG, Bancroft J, Johnstone EC. Affective symptoms in women attending a menopause clinic. Br J Psychiatry. 1994; 164 (4): 513–516.
    1. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: The Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2006; 63 (4): 385–390.
    1. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006; 63 (4): 375–382.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth ed. Arlington, VA: American Psychiatric Publishing; 2013. pp 5–25. ISBN 978-0-89042-555-8.
    1. Calleja N. Inventario de Escalas Psicosociales en México 1984–2005 México: Universidad Autónoma de México; Facultad de Psicología; 2011. pp 230.
    1. Bobes JB, Bulbena A, Luque A, Dal-Ré R, Ballesteros J, Ibarra N, et al. Evaluación psicométrica comparativa de las versiones en español de 6, 17 y 21 ítems de la Escala de valoración de Hamilton para la evaluación de la depresión. Med Clin. 2003; 120 (18): 693–700.
    1. Ramos-Brieva JCA. Validación de la versión castellana de la escala de Hamilton para la depresión. Actas Luso-Esp Neurol Psiquiatr. 1986; (14): 324–334.
    1. Suárez-Mendoza AA, Cardiel MH, Caballero-Uribe CV, Ortega-Soto HA, Márquez-Marín M. Measurement of depression in Mexican patients with rheumatoid arthritis: validity of the Beck Depression Inventory. Arthritis Care Res. 1997; 10 (3): 194–9.
    1. Greene JG. Constructing a standard climacteric scale. Maturitas. 1998; 29: 25–31.
    1. Hernández-Valencia M, Córdova-Pérez N, Basurto L, Saucedo R, Vargas C, Vargas A, et al. Frecuencia de los síntomas del síndrome climatérico. Ginecol Obstet Mex. 2010; 78 (4): 232–237.
    1. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The emperor´s new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prev Treat. 2002; 5, article 23. Available: .
    1. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. London: Clinical Practice Guideline; 2004; 23 pp 670.
    1. Gibbons RD, Hur K, Brown H, Davis JM, Mann JJ. Who benefits from antidepressants? Synthesis of 6-week patient-level outcomes from double-blind placebo controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012; 69 (6): 572–579. 10.1001/archgenpsychiatry.2011.2044
    1. Jonas W, Jacobs J. Healing with Homeopathy. New York Warner; 1996.
    1. Thompson EA. Alternative and complementary therapies for the menopause: a homeopathic approach. Maturitas. 2010; 66: 350–354. 10.1016/j.maturitas.2010.02.003
    1. Bordet MF, Colas A, Marijnen P, Masson JL, Trichard M. Treating hot flushes in menopausal women with homeopathic treatment—Results of an observational study. Homeopathy. 2008; 97: 10–15. 10.1016/j.homp.2007.11.005
    1. Jacobs J, Hermann P, Heron K, Olsen S, Vaughters L. Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled study. J Altern Complement Med. 2005; 11 (1): 21–27.
    1. Davidson JRT, Crawford C, Ives JA, Jonas WB. Homeopathic treatments in psychiatry: a systematic review of randomized placebo-controlled studies. J Clin Psychiatry. 2011; 72 (6): 795–805. 10.4088/JCP.10r06580
    1. Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, et al. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010; 71 (6): 682–688. 10.4088/JCP.10r05976blu
    1. Jonas WB, Kaptchuk YJ, Linde K. A critical overview of homeopathy. Ann Intern Med. 2003; 138 (5): 393–399.
    1. Linde K, Melchart D. Randomized controlled trials of individualized homeopathy: a state-of-the-art review. J Altern Complement Med. 1998; 4 (4): 371–388.
    1. Ernst E. Homeopathy: what does the “best” evidence tell us? Med J Aust. 2010; 192 (8): 458–460.
    1. Shang A, Huwiler-Müntener K, Nartey L, Jüni P, Dörig S, Steme JA, et al. Are the clinical effects of homeopathy placebo effects? Comparative study of placebo-controlled trials of homeopathy and allopathy. Lancet. 2005; 366 (9487): 726–732.
    1. Lüdke R, Rutten ALB. The conclusions on the effectiveness of homeopathy highly depend on the set of analyzed trials. J Clin Epidemiol. 2008; 61 (12): 1197–1204. 10.1016/j.jclinepi.2008.06.015
    1. Bell IR, Lewis DA, Brooks AJ, Schwartz GE, Lewis SE, Walsh BT, et al. Improved clinical status in fibromyalgia patients treated with individualized homeopathic remedies versus placebo. Rheumatology. 2004; 43 (5): 577–82.
    1. Adler UC, Paiva NMP, Cesar AT, Adler MS, Molina A, Padula AE, et al. Homeopathic individualized Q-potencies versus fluoxetine for moderate to severe depression: double-blind, randomized non-inferiority trial. Evid Based Complement Altern Med. 2009. Available: . Advanced Access published on August 17.
    1. Macías-Cortés EC, Aguilar-Faisal L, Asbun-Bojalil J. Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial. Trials. 2013; 14: 105 10.1186/1745-6215-14-105
    1. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement updated guidelines for reporting parallel group randomized trials. PLoS Med. 2010; 24 (3) e[0025]: 7.
    1. Dean ME, Coulter MK, Fisher P, Jobst KA, Walach H. Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT. J Altern Complement Med. 2007; 13 (1): 19–23.
    1. Chan AW, Tetzlaff JM, Gфtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013. Available: http://346:e7586 10.1136/bmj.e7586
    1. Nemeroff CB, Thase M. A double-blind, placebo controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res. 2007; 41: 351–359.
    1. Pinto-Meza A, Usall J, Serrano-Blanco A, Suárez D, Haro JM. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J Affect Dis. 2006; 93: 53–60.
    1. Kornstein SG, Pedersen RD, Holland PJ, Nemeroff CB, Rothschild AJ, Thase MB, et al. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the prevent study. J Clin Psychiatry. 2014; 75 (1): 62–68. 10.4088/JCP.12m07841
    1. Levine TR, Hullett CR. Eta squared, partial eta squared, and misreporting of effect size in communication research. Human Comm Research. 2002; 28 (4): 612–625.
    1. Fournier JC, De Rubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity. A patient-level meta-analysis. JAMA. 2010; 303 (1): 47–53. 10.1001/jama.2009.1943
    1. Snappin SM. Non inferiority trials. Curr Control Trials Cardiovasc Med. 2000; 1: 19–21
    1. Dawes SE, Suarez P, Vaida F, Marcotte TD, Atkinson JH, Grant I, et al. Demographic influences and suggested cut-scores for the Beck Depression Inventory in a non-clinical Spanish population from the US-Mexico border region. Int J Cult Ment Health. 2010; 3(1): 34–42. 10.1080/17542860903533640
    1. Ferrari G, Agnew-Davies R, Bailey J, Howard L, Howarth E, Peters TJ, et al. Domestic violence and mental health: a cross-sectional survey of women seeking help from domestic violence support services Glob Health Action. 2014; 7: 25519 Available: 10.3402/gha.v7.25519.
    1. Instituto Nacional de Estadística y Geografía INEGI. Mujeres y hombres en México 2013. pp 126.
    1. Becker KD, Stuewig J, McCloskey LA. Traumatic stress symptoms of women exposed to different forms of childhood victimization and intimate partner violence. J Interpers Violence. 2010; 25: 1699–715. 10.1177/0886260509354578
    1. Koenig MA, Ahmed S, Hossain MB, Mozumder KA. Women’s status and domestic violence in rural Bangladesh: individual and community-level effects. Demography. 2003; 40: 269–88.
    1. Jewkes R. Intimate partner violence: causes and prevention. Lancet. 2002; 359: 1423–9.
    1. Rapkin AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol. 2007; 196: 97–106.
    1. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrel K. Menopause and metabolic syndrome. The Study of Women's Health across the Nation. Arch Intern Med. 2008; 168 (14): 1568–1575. 10.1001/archinte.168.14.1568
    1. Carroll DG, Kelley KW. Use of antidepressants for management of hot flashes. Pharmacotherapy. 2009; 29 (11): 1357–1374. 10.1592/phco.29.11.1357
    1. Carrasco JL, Sandner C. Clinical effects or pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract. 2005; 59 (12): 1428–1434.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera